West Pharmaceutical Services Inc. (WST) Holdings Cut by American Century Companies Inc.
American Century Companies Inc. lowered its holdings in shares of West Pharmaceutical Services Inc. (NYSE:WST) by 12.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 669,842 shares of the medical instruments supplier’s stock after selling 91,261 shares during the quarter. American Century Companies Inc.’s holdings in West Pharmaceutical Services were worth $66,093,000 at the end of the most recent reporting period.
Other hedge funds have also modified their holdings of the company. Citigroup Inc. boosted its position in West Pharmaceutical Services by 95.1% during the second quarter. Citigroup Inc. now owns 1,569 shares of the medical instruments supplier’s stock worth $148,000 after purchasing an additional 765 shares in the last quarter. Grandfield & Dodd LLC purchased a new position in West Pharmaceutical Services during the third quarter worth approximately $201,000. Nomura Holdings Inc. purchased a new position in West Pharmaceutical Services during the second quarter worth approximately $201,000. Private Advisor Group LLC purchased a new position in West Pharmaceutical Services during the third quarter worth approximately $202,000. Finally, Stephens Inc. AR purchased a new position in West Pharmaceutical Services during the third quarter worth approximately $210,000. Institutional investors own 92.69% of the company’s stock.
A number of equities analysts have issued reports on WST shares. Bank of America downgraded West Pharmaceutical Services from a “buy” rating to a “neutral” rating and set a $98.00 price target on the stock. in a research report on Tuesday, October 17th. Wells Fargo & Co increased their price target on West Pharmaceutical Services from $105.00 to $112.00 and gave the stock an “outperform” rating in a research report on Friday, October 27th. Zacks Investment Research downgraded West Pharmaceutical Services from a “hold” rating to a “sell” rating in a research report on Saturday, January 6th. Finally, Goldman Sachs Group began coverage on West Pharmaceutical Services in a research report on Wednesday, January 24th. They issued a “neutral” rating and a $110.00 target price on the stock. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $108.17.
West Pharmaceutical Services Inc. (NYSE:WST) opened at $91.25 on Friday. The firm has a market capitalization of $6,713.95, a P/E ratio of 36.35, a PEG ratio of 1.92 and a beta of 1.04. West Pharmaceutical Services Inc. has a 1 year low of $77.97 and a 1 year high of $103.36. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.59 and a quick ratio of 1.87.
The company also recently announced a quarterly dividend, which was paid on Thursday, February 1st. Stockholders of record on Thursday, January 18th were given a $0.14 dividend. The ex-dividend date of this dividend was Wednesday, January 17th. This represents a $0.56 annualized dividend and a dividend yield of 0.61%. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 22.31%.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services Inc. (NYSE:WST).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.